Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

ClinicalTrials.gov ID: NCT01191840

Public ClinicalTrials.gov record NCT01191840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to accurately determine the length of appropriate drug treatment for staphylococcal blood stream infection. The study seeks to address important information about the management of staphylococcal blood stream infections.

Study identification

NCT ID
NCT01191840
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Duke University
Other
Enrollment
509 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2011
Primary completion
Mar 3, 2017
Completion
Mar 3, 2017
Last update posted
Jan 4, 2018

2011 – 2017

United States locations

U.S. sites
14
U.S. states
10
U.S. cities
14
Facility City State ZIP Site status
University of Alabama, Birmingham Birmingham Alabama 35294
David Geffen School of Medicine UCLA Los Angeles California 90095
University of Colorado Denver Colorado 80204
University of Mass Worcester Massachusetts 01752
Henry Ford Hospital Detroit Michigan 48202
William Beaumont Hospital Royal Oak Michigan 48073
University of Nebraska Medical Center Omaha Nebraska 68198
Albert Einstein College of Medicine The Bronx New York 10467
Carolina Medical Center Charlotte North Carolina 28207
Duke University Medical Center Durham North Carolina 27705
Brody School of Medicine at ECU Greenville North Carolina 27834
Medical University of South Carolina Charleston South Carolina 29425
Greenville Hospital System Greenville South Carolina 29605
UT MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01191840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 4, 2018 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01191840 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →